CASIF (CASI Pharmaceuticals) Shiller PE Ratio: (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASIF CASI Pharmaceuticals Inc CASIF
29 GF Score
Price $0.15
GF Value $1.10
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CASI Pharmaceuticals  (OTCPK:CASIF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CASI Pharmaceuticals Shiller PE Ratio Related Terms


CASI Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Shiller PE Ratio Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CASI Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CASIF vs DCOY, PKTX, BIXT: Shiller PE Ratio Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Shiller PE Ratio falls into.


CASIF
29GF Score
CASI Pharmaceuticals Inc CASIF
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CASI Pharmaceuticals's E10 for the quarter that ended in Dec. 2025 is calculated as:

For example, CASI Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.36/115.8323*115.8323
=-0.360

Current CPI (Dec. 2025) = 115.8323.

CASI Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201603 -0.400 102.200 -0.453
201606 -0.800 101.400 -0.914
201609 -0.300 102.400 -0.339
201612 -0.444 102.600 -0.501
201703 -0.300 103.200 -0.337
201706 -0.400 103.100 -0.449
201709 -0.300 104.100 -0.334
201712 -0.800 104.500 -0.887
201803 -0.500 105.300 -0.550
201806 -0.700 104.900 -0.773
201809 -1.000 106.600 -1.087
201812 -1.000 106.500 -1.088
201903 -0.900 107.700 -0.968
201906 -1.600 107.700 -1.721
201909 -1.000 109.800 -1.055
201912 -1.300 111.200 -1.354
202003 -0.900 112.300 -0.928
202006 -0.900 110.400 -0.944
202009 -1.400 111.700 -1.452
202012 -1.170 111.500 -1.215
202103 -1.100 112.662 -1.131
202106 -0.500 111.769 -0.518
202109 -0.730 112.215 -0.754
202112 -0.390 113.108 -0.399
202203 -0.620 114.335 -0.628
202206 -0.560 114.558 -0.566
202209 -0.380 115.339 -0.382
202212 -1.440 115.116 -1.449
202303 -0.450 115.116 -0.453
202306 -0.770 114.558 -0.779
202309 -0.350 115.339 -0.351
202312 -0.460 114.781 -0.464
202403 -0.710 115.227 -0.714
202406 -0.520 114.781 -0.525
202409 -0.550 115.785 -0.550
202412 -0.790 114.893 -0.796
202503 -0.690 115.116 -0.694
202506 -0.860 114.907 -0.867
202509 -0.670 115.471 -0.672
202512 -0.360 115.832 -0.360

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.15 is trading 86.5% below its estimated GF Value™ of $1.10. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • Shiller PE Ratio:
  • GF Value™: $1.10 vs. price of $0.15 (86.5% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for CASIF

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$1.10
GF Value